Safety and Effectiveness of Preoperative Intravenous Dexamethasone for Minimally Invasive Spine Fusion Surgery MIS-TLIF in Adults Aged 50 to 80

What this Trial Is About

Researchers are evaluating the use of Dexamethasone given before minimally invasive spine fusion surgery MIS-TLIF to reduce postoperative back pain. This study aims to improve surgical outcomes with minimal side effects by comparing Dexamethasone to a placebo. The trial also investigates morphine use, side effects like nausea, infection rates, blood sugar levels, spinal fusion success, and hospital stay duration. Participants receive either an intravenous injection of Dexamethasone or a normal saline placebo before their MIS-TLIF surgery, which involves fusing 1-2 spinal levels using a less invasive technique. The study includes a randomized, quadruple-blind design comparing these two groups to assess the effectiveness and safety of preemptive Dexamethasone. During the study, back pain and medication use are measured at multiple points up to 12 weeks after surgery. Fusion rates are checked at 6 months, and hospital stay length is monitored for a year. Researchers will also track complications and adverse reactions to gather comprehensive data on recovery and safety. The total participation spans from surgery through a year of follow-up assessments.

Efficacy and Safety of Preemptive Intravenous Dexamethasone in MIS-TLIF